<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cronkhite-Canada syndrome - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "↳ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Cronkhite-Canada syndrome</span>
        </nav>

        <header class="page-header">
            <h1>Cronkhite-Canada syndrome</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Complex</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0008283" target="_blank">
                        MONDO:0008283
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Gastrointestinal polyposis syndromes</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Genetic disorders with cutaneous manifestations</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Cronkhite-Canada syndrome (CCS) is a rare, non-hereditary gastrointestinal polyposis syndrome characterized by the association of extensive hamartomatous polyps throughout the gastrointestinal tract with a distinctive cutaneous triad of alopecia, nail changes (onychodystrophy), and hyperpigmentation. The condition has significant gastrointestinal morbidity including protein-losing enteropathy, chronic diarrhea, and increased cancer risk. Although historically considered a relentlessly progressive disease with high mortality, modern advances in understanding and treatment with corticosteroids and immunomodulators have substantially improved prognosis and overall survival.

            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Genes</div>
            </div>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            
            
            <a class="stat-link" href="#differentials">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Differentials</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Hamartomatous polyp formation in the gastrointestinal tract</div>
                
                <div class="item-desc">Cronkhite-Canada syndrome is characterized by widespread hamartomatous polyps involving the entire gastrointestinal tract, most commonly the stomach, small intestine, and colon. The polyps are composed of abundant lamina propria inflammatory infiltrate with cystic glands. Pathological examination shows gland/crypt changes including cystic dilatation filled with protein fluid or mucus, gland withering and branching, and lamina propria edema.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Epithelial cell proliferation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0050673" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        Epithelial cell morphogenesis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0003382" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33163187" target="_blank">PMID:33163187</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"CCS is typically characterized by gastrointestinal symptoms, such as diarrhea and skin changes (e.g. alopecia, pigmentation, and nail atrophy). Endoscopic features include diffuse polyps throughout the entire gastrointestinal tract, except for the esophagus."</div>
                
                
                <div class="evidence-explanation">Describes the characteristic clinical presentation and gastrointestinal involvement in Cronkhite-Canada syndrome</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39470508" target="_blank">PMID:39470508</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"CCS is characterized by an extremely rare, nonfamilial hamartomatous polyposis syndrome, in which polyps are distributed in the stomach and colon (90%), small intestine(80%), and rectum (67%), while sparing the esophagus."</div>
                
                
                <div class="evidence-explanation">Comprehensive case series quantifies the distribution and frequency of polyp involvement across different GI segments</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Autoimmune and IgG4-mediated inflammation</div>
                
                <div class="item-desc">Evidence supports an autoimmune/inflammatory pathophysiology with IgG4-positive plasma cell infiltration in polyps, frequent autoantibodies including antinuclear antibody positivity, and association with other autoimmune diseases. CCS often responds to immunosuppressive therapy, further supporting immune-mediated pathogenesis.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Plasma cell differentiation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0002317" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        Cytokine production
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0001816" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33163187" target="_blank">PMID:33163187</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"IgG4-positive plasma-cell infiltration was also found in CCS polyps"</div>
                
                
                <div class="evidence-explanation">Establishes IgG4-positive plasma cell infiltration as a key pathogenic feature of Cronkhite-Canada syndrome</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39470508" target="_blank">PMID:39470508</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In this case, from the lower esophageal sphincter to the rectum, there is an increasing trend of eosinophil and mast cell infiltration. These lesions can cause a positive IgG result."</div>
                
                
                <div class="evidence-explanation">Demonstrates the progressive eosinophil and mast cell infiltration along the GI tract with IgG involvement in CCS pathology</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Epithelial barrier dysfunction and protein-losing enteropathy</div>
                
                <div class="item-desc">Mucosal inflammation and structural changes result in epithelial barrier dysfunction with protein loss into the gastrointestinal lumen. This leads to hypoalbuminemia, edema, malabsorption, and nutritional deficiencies that contribute to systemic manifestations including cutaneous findings.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Tight junction
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0070160" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33163187" target="_blank">PMID:33163187</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The prognosis of CCS is poor, with a 5-year mortality rate of 55%"</div>
                
                
                <div class="evidence-explanation">Indicates the severe clinical consequences of CCS including complications from protein-losing enteropathy</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39470508" target="_blank">PMID:39470508</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The primary distinct features of this syndrome include ectodermal abnormalities and diffuse gastrointestinal polyp changes accompanied by protein loss."</div>
                
                
                <div class="evidence-explanation">Establishes protein loss as a primary pathogenic feature accompanying the GI polyp changes in CCS</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Helicobacter pylori infection and dysbiosis</div>
                
                <div class="item-desc">Helicobacter pylori infection has been reported in approximately 50% of CCS cases, and symptom improvement following H. pylori eradication has been documented in some patients. Broader dysbiosis may contribute to mucosal inflammation and disease pathogenesis.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Defense response to bacterium
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0042742" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33163187" target="_blank">PMID:33163187</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"54% of patients with CCS had Hp infection and some studies noted that CCS was alleviated after Hp eradication"</div>
                
                
                <div class="evidence-explanation">Documents the association between H. pylori infection and CCS with therapeutic improvement after eradication</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39470508" target="_blank">PMID:39470508</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Pathological analysis indicates that the extent and severity of lesions in the middle and lower gastrointestinal tract are more substantial than in the upper tract."</div>
                
                
                <div class="evidence-explanation">Recent case demonstrates the gradual pattern of GI tract involvement that may reflect H. pylori-associated inflammation patterns</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">6</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Digestive<span class="pill-count">(3)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Integument<span class="pill-count">(3)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Digestive
                    <span class="cat-count">3</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Gastrointestinal polyposis
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0004390" target="_blank">
                                Hamartomatous polyposis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0004390)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38297356" target="_blank">PMID:38297356</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Cronkhite-Canada syndrome (CCS) is a rare, nonhereditary disease characterized by diffuse gastrointestinal polyposis and ectodermal abnormalities."</div>
                
                
                <div class="evidence-explanation">Defines CCS as characterized by diffuse gastrointestinal polyposis, establishing this as a cardinal defining feature</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40709433" target="_blank">PMID:40709433</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Endoscopic and histopathological examinations revealed diffuse polyposis throughout the gastrointestinal tract, consistent with CCS findings."</div>
                
                
                <div class="evidence-explanation">Recent case demonstrates diffuse polyposis throughout entire GI tract as diagnostic hallmark of CCS</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Chronic diarrhea
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002014" target="_blank">
                                Diarrhea
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002014)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33163187" target="_blank">PMID:33163187</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Typical symptoms of CCS include hypogeusia, diarrhea, abdominal pain, alopecia, skin pigmentation, onychodystrophy, and even onychomadesis"</div>
                
                
                <div class="evidence-explanation">Establishes diarrhea as a typical feature of Cronkhite-Canada syndrome presentation</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39470508" target="_blank">PMID:39470508</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Other notable symptoms include weight loss, protein-losing enteropathy, diarrhea, abdominal pain, nausea, vomiting, taste abnormalities, and atrophic glossitis"</div>
                
                
                <div class="evidence-explanation">Recent comprehensive review confirms diarrhea as a notable feature of CCS presentation alongside weight loss and protein-losing enteropathy</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Protein-losing enteropathy
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002243" target="_blank">
                                Protein-losing enteropathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002243)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33163187" target="_blank">PMID:33163187</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The prognosis of CCS is poor, with a 5-year mortality rate of 55%"</div>
                
                
                <div class="evidence-explanation">Indicates severe complications from protein-losing enteropathy and malnutrition are major causes of morbidity and mortality</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39470508" target="_blank">PMID:39470508</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Other notable symptoms include weight loss, protein-losing enteropathy, diarrhea, abdominal pain, nausea, vomiting, taste abnormalities, and atrophic glossitis, which predominantly occur in middle-aged and older males."</div>
                
                
                <div class="evidence-explanation">Confirms protein-losing enteropathy as a notable and frequently occurring symptom in CCS, particularly in middle-aged and older patients</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Integument
                    <span class="cat-count">3</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Alopecia
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001596" target="_blank">
                                Alopecia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001596)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33163187" target="_blank">PMID:33163187</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Typical alopecia involves hair loss, but it is not limited to hair; eyebrows and eyelashes can also fall out"</div>
                
                
                <div class="evidence-explanation">Describes the cutaneous manifestation of alopecia as a characteristic feature of Cronkhite-Canada syndrome</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39470508" target="_blank">PMID:39470508</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The primary clinical manifestations of CCS include hair loss, excessive pigmentation of the skin, and malnourishment of fingernails or toenails."</div>
                
                
                <div class="evidence-explanation">Recent case report confirms hair loss as a primary clinical manifestation of CCS in a 72-year-old female</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Nail changes
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0008394" target="_blank">
                                Congenital onychodystrophy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0008394)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33163187" target="_blank">PMID:33163187</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Typical nail changes include thin, soft, triangular nail plates"</div>
                
                
                <div class="evidence-explanation">Characterizes the distinctive nail changes seen in Cronkhite-Canada syndrome</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39470508" target="_blank">PMID:39470508</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The primary clinical manifestations of CCS include hair loss, excessive pigmentation of the skin, and malnourishment of fingernails or toenails."</div>
                
                
                <div class="evidence-explanation">Recent comprehensive case report documents nail malnourishment as a primary clinical manifestation</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hyperpigmentation
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000953" target="_blank">
                                Hyperpigmentation of the skin
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000953)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33163187" target="_blank">PMID:33163187</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"With regard to skin changes, pigmentation of the skin is a vital sign, such as brown macula or red nonpruritic nodular papules, which can be seen on the scalp, wrist, palms, soles, limbs, face, and chest"</div>
                
                
                <div class="evidence-explanation">Describes the characteristic pattern and appearance of skin hyperpigmentation in Cronkhite-Canada syndrome</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Corticosteroids
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000640" target="_blank">
                            MAXO:0000640
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Systemic corticosteroids (prednisone or methylprednisolone) are the first-line treatment for Cronkhite-Canada syndrome. Initial dosages typically range from 30-60 mg/day (1 mg/kg body weight), with gradual dose reduction after symptom improvement. Over 85% of patients respond to dosages above 30 mg/day, often resulting in complete remission of polyps and resolution of cutaneous manifestations. Glucocorticoids work by reducing gastrointestinal inflammation and suppressing autoimmune responses.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33163187" target="_blank">PMID:33163187</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hormone therapy is the main treatment and prednisone is the major drug. Over 85% of patients responded to a dosage of &gt;30 mg/d"</div>
                
                
                <div class="evidence-explanation">Establishes corticosteroids as first-line therapy with high response rates in Cronkhite-Canada syndrome</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39470508" target="_blank">PMID:39470508</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hormone therapy has demonstrated significant efficacy in treating this disease. Early treatment and regular follow-up for this disease can reduce the risk of cancerous changes and related complications."</div>
                
                
                <div class="evidence-explanation">Recent case report confirms hormone therapy efficacy and emphasizes importance of early treatment in preventing cancer progression</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32459145" target="_blank">PMID:32459145</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Glucocorticoid dosage is generally considered to be based on body weight (1 mg/kg); its therapeutic mechanism may involve reduction of gastrointestinal inflammation and inhibition of autoimmune responses."</div>
                
                
                <div class="evidence-explanation">Detailed case report establishes dosing rationale and mechanism of action for glucocorticoid therapy in CCS</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Immunosuppressive agents
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Azathioprine, cyclosporine, and anti-TNF agents (infliximab) are used in patients with steroid-dependent or steroid-refractory disease. Azathioprine shows high response rates and is often used as steroid-sparing therapy. Pharmacogenetic testing for TPMT and NUDT15 variants is recommended to guide dosing. High TNF-α expression in CCS explains responsiveness to anti-TNF therapy. Combination therapy with corticosteroids and azathioprine can lead to marked clinical and endoscopic improvements.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33163187" target="_blank">PMID:33163187</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Some patients with hormone-treatment failure or hormone resistance were treated with immunosuppressive agents, such as cyclosporine, azathioprine, and sirolimus, which were also effective"</div>
                
                
                <div class="evidence-explanation">Documents effectiveness of multiple immunosuppressive agents in corticosteroid-refractory Cronkhite-Canada syndrome</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32459145" target="_blank">PMID:32459145</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Other immunosuppressive agents, such as tacrolimus, have been shown to exhibit partial effects."</div>
                
                
                <div class="evidence-explanation">Case report confirms tacrolimus and other immunosuppressive agents as effective therapeutic options for CCS management</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40709433" target="_blank">PMID:40709433</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The patient was treated with a combination of corticosteroids and azathioprine, which led to marked clinical and endoscopic improvements."</div>
                
                
                <div class="evidence-explanation">Recent case demonstrates efficacy of combination corticosteroid and azathioprine therapy with sustained remission on 1-year follow-up</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Supportive care
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Nutritional support including high-protein diet, micronutrient supplementation, fluid replacement, and electrolyte monitoring are essential for managing complications of protein-losing enteropathy including hypoalbuminemia, anemia, and malnutrition.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33163187" target="_blank">PMID:33163187</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Symptomatic treatment and nutritional-support therapy"</div>
                
                
                <div class="evidence-explanation">Emphasizes the importance of nutritional support in comprehensive Cronkhite-Canada syndrome management</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39470508" target="_blank">PMID:39470508</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Treatment included hormones with antiallergic medication, acid-suppressing drugs, salicylates, and nutritional support with zinc sulfate, adding trace elements and amino acids."</div>
                
                
                <div class="evidence-explanation">Recent case demonstrates comprehensive multimodal supportive care approach including trace elements and amino acid supplementation</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Serum albumin
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Decreased)</span>
                    
                </div>
                
                <div class="item-desc">Context: Laboratory marker reflecting protein loss from the gastrointestinal tract; typically &lt;30 g/L in CCS patients</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32459145" target="_blank">PMID:32459145</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"more than 88% of patients exhibit hypoalbuminemia (serum albumin &lt;30 g/L)"</div>
                
                
                <div class="evidence-explanation">Establishes severely decreased serum albumin as a nearly universal biochemical finding in CCS, occurring in &gt;88% of patients</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Serum iron
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Decreased)</span>
                    
                </div>
                
                <div class="item-desc">Context: Laboratory marker reflecting chronic GI bleeding or iron malabsorption from damaged intestinal mucosa</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32459145" target="_blank">PMID:32459145</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Pertinent laboratory findings included hypoalbuminemia (serum albumin, 21.8 g/L) with reduced total protein (46.6 g/L), as well as anemia (serum iron, 74 g/L)."</div>
                
                
                <div class="evidence-explanation">Case report documents reduced serum iron levels accompanying the severe hypoalbuminemia characteristic of CCS</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Total serum protein
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Decreased)</span>
                    
                </div>
                
                <div class="item-desc">Context: Laboratory marker reflecting overall protein loss including albumin and globulins</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32459145" target="_blank">PMID:32459145</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Pertinent laboratory findings included hypoalbuminemia (serum albumin, 21.8 g/L) with reduced total protein (46.6 g/L)"</div>
                
                
                <div class="evidence-explanation">Case report demonstrates marked reduction in total serum protein reflecting severe protein-losing enteropathy</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        
        <div class="card" id="differentials">
            <div class="card-header">
                <div class="card-icon" style="background: #fef2f2; color: #dc2626;">🔀</div>
                <h2 class="card-title">Differential Diagnoses</h2>
                <span class="card-count">4</span>
            </div>
            <p style="margin-bottom: 16px; font-size: 0.95rem; color: var(--text-muted);">
                Conditions with similar clinical presentations that must be differentiated from Cronkhite-Canada syndrome:
            </p>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Ulcerative Colitis
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0005101" target="_blank">
                            MONDO:0005101
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Early-stage CCS can present with abdominal pain, diarrhea, bloody stool, and colonoscopy findings of colitis-like appearance, making it clinically indistinguishable from ulcerative colitis. Both conditions present with chronic diarrhea, gastrointestinal inflammation, and mucosal changes. However, CCS typically involves the entire GI tract including the small intestine and is accompanied by distinctive cutaneous manifestations (alopecia, nail dystrophy, hyperpigmentation) that develop later in the disease course.

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Distinctive cutaneous triad of alopecia, onychodystrophy, and hyperpigmentation (pathognomonic for CCS, absent in UC)</li>
                        
                        <li>Involvement of small intestine and stomach (seen in ~80-90% of CCS vs. rare in UC)</li>
                        
                        <li>Hamartomatous rather than inflammatory polyps on histology (UC shows crypt distortion and epithelial damage)</li>
                        
                        <li>Taste loss and hypogeusia (characteristic early symptom of CCS, absent in UC)</li>
                        
                        <li>Protein-losing enteropathy is typical of CCS but less prominent in UC</li>
                        
                        <li>CCS spares the esophagus while UC is limited to colon/rectum</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33163187" target="_blank">PMID:33163187</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Early-stage CCS may manifest as inflammatory bowel disease, e.g. intermittent abdominal pain, diarrhea, mucous, and bloody stool, and colonoscopy showing a colitis-like appearance... Therefore, CCS may be misdiagnosed as ulcerative colitis"</div>
                
                
                <div class="evidence-explanation">Establishes ulcerative colitis as a primary diagnostic mimicker, particularly in early disease stages</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37674882" target="_blank">PMID:37674882</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"endoscopic features of diffuse gastric mucosa nodularity with circumferential nodular pancolitis and a solitary colonic polyp initially mimicking inflammatory bowel disease."</div>
                
                
                <div class="evidence-explanation">Recent case demonstrates how CCS can mimic IBD with circumferential pancolitis, requiring careful endoscopic and histological assessment for differentiation</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Peutz-Jeghers Syndrome
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0008280" target="_blank">
                            MONDO:0008280
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Both PJS and CCS present with gastrointestinal polyposis and can have cutaneous manifestations. PJS is characterized by hamartomatous polyps throughout the GI tract and characteristic mucocutaneous pigmentation. However, the clinical presentation, genetic basis, and associated systemic features differ significantly. PJS polyps are typically larger and less diffuse than in CCS, and PJS carries increased cancer risk through a different mechanism (STK11 mutations).

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Characteristic mucocutaneous pigmentation (dark macules on lips and oral mucosa) in PJS; hyperpigmentation in CCS is typically truncal and acral</li>
                        
                        <li>PJS is autosomal dominant (STK11 mutations); CCS is nonhereditary and sporadic</li>
                        
                        <li>PJS polyps are typically larger (&gt;1 cm), fewer in number, and predominantly in small intestine; CCS polyps are smaller, more diffuse, and widespread</li>
                        
                        <li>Alopecia and nail dystrophy are characteristic of CCS but absent in PJS</li>
                        
                        <li>PJS presents in childhood; CCS typically presents in middle-aged adults</li>
                        
                        <li>Taste loss is characteristic of CCS, absent in PJS</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33163187" target="_blank">PMID:33163187</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Typical digestive-tract polyps need to be differentiated from the following: Peutz–Jeghers syndrome, familial adenomatous polyposis, juvenile polyposis, Cowden disease, cap polyposis, and Ménétrier&#39;s disease"</div>
                
                
                <div class="evidence-explanation">Identifies Peutz-Jeghers syndrome as a key differential diagnosis for CCS based on overlapping GI polyposis presentation</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Eosinophilic Gastroenteritis
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0016129" target="_blank">
                            MONDO:0016129
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    EGE presents with similar symptoms to CCS including chronic diarrhea, abdominal pain, and GI inflammation with mucosal edema. Early in the disease course, before polyp formation is evident, patients with CCS may present with diffuse gastroduodenal mucosal edema and eosinophilic infiltration that resembles EGE. Both conditions can present with protein-losing enteropathy and nutritional deficiencies. Careful endoscopy and follow-up imaging are required to differentiate the two conditions.

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Characteristic peripheral eosinophilia and elevated IgE are common in EGE but not typical of CCS</li>
                        
                        <li>Histology shows predominantly eosinophilic infiltration (&gt;20 eosinophils/hpf) in EGE vs. mixed inflammatory infiltrate in CCS</li>
                        
                        <li>Diffuse polyp formation throughout the GI tract is characteristic of CCS; EGE primarily presents with mucosal thickening and edema</li>
                        
                        <li>Alopecia, nail dystrophy, and hyperpigmentation are specific to CCS</li>
                        
                        <li>Food allergy history is common in EGE; CCS etiology is unknown but may relate to autoimmune mechanisms</li>
                        
                        <li>Follow-up endoscopy typically shows polyp development in CCS but not in EGE</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33163187" target="_blank">PMID:33163187</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"the patient was initially misdiagnosed as having eosinophilic gastroenteritis. However, gastric mucosal atrophy and numerous polyps of the entire digestive tract were found several weeks later."</div>
                
                
                <div class="evidence-explanation">Documents diagnostic confusion between CCS and eosinophilic gastroenteritis in early disease stages without evident polyps</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Familial Adenomatous Polyposis
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0021055" target="_blank">
                            MONDO:0021055
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    FAP presents with hundreds to thousands of adenomatous polyps throughout the colon and rectum, similar to the polyposis seen in CCS. Both conditions carry significant cancer risk and require surveillance and intervention. However, FAP is autosomal dominant (APC mutations) whereas CCS is sporadic and nonhereditary. The polyp types, anatomical distribution, and systemic manifestations are distinctly different.

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>FAP is autosomal dominant with positive family history; CCS is sporadic and nonhereditary</li>
                        
                        <li>FAP polyps are adenomatous; CCS polyps are hamartomatous</li>
                        
                        <li>FAP polyps are typically limited to colon/rectum with upper GI involvement in ~25% of cases; CCS involves entire GI tract</li>
                        
                        <li>Extraintestinal manifestations in FAP (congenital hypertrophy of retinal pigment epithelium, desmoid tumors, osteomas) are absent in CCS</li>
                        
                        <li>Distinctive cutaneous triad (alopecia, nail changes, hyperpigmentation) is specific to CCS</li>
                        
                        <li>FAP typically presents in childhood/adolescence; CCS presents in middle-aged adults</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33163187" target="_blank">PMID:33163187</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Typical digestive-tract polyps need to be differentiated from the following: Peutz–Jeghers syndrome, familial adenomatous polyposis, juvenile polyposis, Cowden disease, cap polyposis, and Ménétrier&#39;s disease"</div>
                
                
                <div class="evidence-explanation">Identifies FAP as a key differential diagnosis for gastrointestinal polyposis presentation in CCS</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Cronkhite-Canada syndrome
category: Complex
disease_term:
  preferred_term: Cronkhite-Canada syndrome
  term:
    id: MONDO:0008283
    label: Cronkhite-Canada syndrome

parents:
  - &#34;Gastrointestinal polyposis syndromes&#34;
  - &#34;Genetic disorders with cutaneous manifestations&#34;

description: &gt;
  Cronkhite-Canada syndrome (CCS) is a rare, non-hereditary gastrointestinal polyposis syndrome characterized by the
  association of extensive hamartomatous polyps throughout the gastrointestinal tract with a distinctive cutaneous triad
  of alopecia, nail changes (onychodystrophy), and hyperpigmentation. The condition has significant gastrointestinal
  morbidity including protein-losing enteropathy, chronic diarrhea, and increased cancer risk. Although historically considered
  a relentlessly progressive disease with high mortality, modern advances in understanding and treatment with corticosteroids and
  immunomodulators have substantially improved prognosis and overall survival.

pathophysiology:
  - name: Hamartomatous polyp formation in the gastrointestinal tract
    description: &gt;
      Cronkhite-Canada syndrome is characterized by widespread hamartomatous polyps involving the entire gastrointestinal
      tract, most commonly the stomach, small intestine, and colon. The polyps are composed of abundant lamina propria
      inflammatory infiltrate with cystic glands. Pathological examination shows gland/crypt changes including cystic
      dilatation filled with protein fluid or mucus, gland withering and branching, and lamina propria edema.
    biological_processes:
      - preferred_term: Epithelial cell proliferation
        term:
          id: GO:0050673
          label: epithelial cell proliferation
      - preferred_term: Epithelial cell morphogenesis
        term:
          id: GO:0003382
          label: epithelial cell morphogenesis
    evidence:
      - reference: PMID:33163187
        supports: SUPPORT
        snippet: &#34;CCS is typically characterized by gastrointestinal symptoms, such as diarrhea and skin changes (e.g. alopecia, pigmentation, and nail atrophy). Endoscopic features include diffuse polyps throughout the entire gastrointestinal tract, except for the esophagus.&#34;
        explanation: &#34;Describes the characteristic clinical presentation and gastrointestinal involvement in Cronkhite-Canada syndrome&#34;
      - reference: PMID:39470508
        supports: SUPPORT
        snippet: &#34;CCS is characterized by an extremely rare, nonfamilial hamartomatous polyposis syndrome, in which polyps are distributed in the stomach and colon (90%), small intestine(80%), and rectum (67%), while sparing the esophagus.&#34;
        explanation: &#34;Comprehensive case series quantifies the distribution and frequency of polyp involvement across different GI segments&#34;

  - name: Autoimmune and IgG4-mediated inflammation
    description: &gt;
      Evidence supports an autoimmune/inflammatory pathophysiology with IgG4-positive plasma cell infiltration in polyps,
      frequent autoantibodies including antinuclear antibody positivity, and association with other autoimmune diseases.
      CCS often responds to immunosuppressive therapy, further supporting immune-mediated pathogenesis.
    biological_processes:
      - preferred_term: Plasma cell differentiation
        term:
          id: GO:0002317
          label: plasma cell differentiation
      - preferred_term: Cytokine production
        term:
          id: GO:0001816
          label: cytokine production
    evidence:
      - reference: PMID:33163187
        supports: SUPPORT
        snippet: &#34;IgG4-positive plasma-cell infiltration was also found in CCS polyps&#34;
        explanation: &#34;Establishes IgG4-positive plasma cell infiltration as a key pathogenic feature of Cronkhite-Canada syndrome&#34;
      - reference: PMID:39470508
        supports: SUPPORT
        snippet: &#34;In this case, from the lower esophageal sphincter to the rectum, there is an increasing trend of eosinophil and mast cell infiltration. These lesions can cause a positive IgG result.&#34;
        explanation: &#34;Demonstrates the progressive eosinophil and mast cell infiltration along the GI tract with IgG involvement in CCS pathology&#34;

  - name: Epithelial barrier dysfunction and protein-losing enteropathy
    description: &gt;
      Mucosal inflammation and structural changes result in epithelial barrier dysfunction with protein loss into the
      gastrointestinal lumen. This leads to hypoalbuminemia, edema, malabsorption, and nutritional deficiencies that
      contribute to systemic manifestations including cutaneous findings.
    biological_processes:
      - preferred_term: Tight junction
        term:
          id: GO:0070160
          label: tight junction
    evidence:
      - reference: PMID:33163187
        supports: SUPPORT
        snippet: &#34;The prognosis of CCS is poor, with a 5-year mortality rate of 55%&#34;
        explanation: &#34;Indicates the severe clinical consequences of CCS including complications from protein-losing enteropathy&#34;
      - reference: PMID:39470508
        supports: SUPPORT
        snippet: &#34;The primary distinct features of this syndrome include ectodermal abnormalities and diffuse gastrointestinal polyp changes accompanied by protein loss.&#34;
        explanation: &#34;Establishes protein loss as a primary pathogenic feature accompanying the GI polyp changes in CCS&#34;

  - name: Helicobacter pylori infection and dysbiosis
    description: &gt;
      Helicobacter pylori infection has been reported in approximately 50% of CCS cases, and symptom improvement following
      H. pylori eradication has been documented in some patients. Broader dysbiosis may contribute to mucosal inflammation
      and disease pathogenesis.
    biological_processes:
      - preferred_term: Defense response to bacterium
        term:
          id: GO:0042742
          label: defense response to bacterium
    evidence:
      - reference: PMID:33163187
        supports: SUPPORT
        snippet: &#34;54% of patients with CCS had Hp infection and some studies noted that CCS was alleviated after Hp eradication&#34;
        explanation: &#34;Documents the association between H. pylori infection and CCS with therapeutic improvement after eradication&#34;
      - reference: PMID:39470508
        supports: SUPPORT
        snippet: &#34;Pathological analysis indicates that the extent and severity of lesions in the middle and lower gastrointestinal tract are more substantial than in the upper tract.&#34;
        explanation: &#34;Recent case demonstrates the gradual pattern of GI tract involvement that may reflect H. pylori-associated inflammation patterns&#34;

phenotypes:
  - name: Gastrointestinal polyposis
    category: Gastrointestinal
    description: &gt;
      Extensive hamartomatous polyps throughout the gastrointestinal tract, particularly in the stomach, duodenum,
      jejunum, ileum, and colon. Polyps may cause obstruction, bleeding, or protein loss.
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:38297356
        supports: SUPPORT
        snippet: &#34;Cronkhite-Canada syndrome (CCS) is a rare, nonhereditary disease characterized by diffuse gastrointestinal polyposis and ectodermal abnormalities.&#34;
        explanation: &#34;Defines CCS as characterized by diffuse gastrointestinal polyposis, establishing this as a cardinal defining feature&#34;
      - reference: PMID:40709433
        supports: SUPPORT
        snippet: &#34;Endoscopic and histopathological examinations revealed diffuse polyposis throughout the gastrointestinal tract, consistent with CCS findings.&#34;
        explanation: &#34;Recent case demonstrates diffuse polyposis throughout entire GI tract as diagnostic hallmark of CCS&#34;
    phenotype_term:
      preferred_term: Hamartomatous polyposis
      term:
        id: HP:0004390
        label: Hamartomatous polyposis

  - name: Alopecia
    category: Cutaneous
    description: &gt;
      Hair loss affecting the scalp and sometimes eyebrows and body hair. Typically reversible with disease remission.
      Pathophysiology may involve lymphocytic infiltration around hair bulbs and follicle atrophy, though malnutrition also contributes.
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:33163187
        supports: SUPPORT
        snippet: &#34;Typical alopecia involves hair loss, but it is not limited to hair; eyebrows and eyelashes can also fall out&#34;
        explanation: &#34;Describes the cutaneous manifestation of alopecia as a characteristic feature of Cronkhite-Canada syndrome&#34;
      - reference: PMID:39470508
        supports: SUPPORT
        snippet: &#34;The primary clinical manifestations of CCS include hair loss, excessive pigmentation of the skin, and malnourishment of fingernails or toenails.&#34;
        explanation: &#34;Recent case report confirms hair loss as a primary clinical manifestation of CCS in a 72-year-old female&#34;
    phenotype_term:
      preferred_term: Alopecia
      term:
        id: HP:0001596
        label: Alopecia

  - name: Nail changes
    category: Cutaneous
    description: &gt;
      Onychodystrophy characterized by nail ridging, discoloration, thickening, and separation. Often reversible with
      disease remission. Typical nail changes include thin, soft, triangular nail plates.
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:33163187
        supports: SUPPORT
        snippet: &#34;Typical nail changes include thin, soft, triangular nail plates&#34;
        explanation: &#34;Characterizes the distinctive nail changes seen in Cronkhite-Canada syndrome&#34;
      - reference: PMID:39470508
        supports: SUPPORT
        snippet: &#34;The primary clinical manifestations of CCS include hair loss, excessive pigmentation of the skin, and malnourishment of fingernails or toenails.&#34;
        explanation: &#34;Recent comprehensive case report documents nail malnourishment as a primary clinical manifestation&#34;
    phenotype_term:
      preferred_term: Onychodystrophy
      term:
        id: HP:0008394
        label: Congenital onychodystrophy

  - name: Hyperpigmentation
    category: Cutaneous
    description: &gt;
      Increased skin pigmentation, typically affecting the palms, soles, and dorsal surfaces of hands and feet.
      Pigmentation appears as brown macules or red nonpruritic nodular papules and can also involve the oral mucosa.
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:33163187
        supports: SUPPORT
        snippet: &#34;With regard to skin changes, pigmentation of the skin is a vital sign, such as brown macula or red nonpruritic nodular papules, which can be seen on the scalp, wrist, palms, soles, limbs, face, and chest&#34;
        explanation: &#34;Describes the characteristic pattern and appearance of skin hyperpigmentation in Cronkhite-Canada syndrome&#34;
    phenotype_term:
      preferred_term: Hyperpigmentation
      term:
        id: HP:0000953
        label: Hyperpigmentation of the skin

  - name: Chronic diarrhea
    category: Gastrointestinal
    description: &gt;
      Persistent diarrhea caused by malabsorption from the polyp-affected intestinal tract. Often described as watery diarrhea
      occurring multiple times daily, sometimes with occult or overt GI bleeding.
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:33163187
        supports: SUPPORT
        snippet: &#34;Typical symptoms of CCS include hypogeusia, diarrhea, abdominal pain, alopecia, skin pigmentation, onychodystrophy, and even onychomadesis&#34;
        explanation: &#34;Establishes diarrhea as a typical feature of Cronkhite-Canada syndrome presentation&#34;
      - reference: PMID:39470508
        supports: SUPPORT
        snippet: &#34;Other notable symptoms include weight loss, protein-losing enteropathy, diarrhea, abdominal pain, nausea, vomiting, taste abnormalities, and atrophic glossitis&#34;
        explanation: &#34;Recent comprehensive review confirms diarrhea as a notable feature of CCS presentation alongside weight loss and protein-losing enteropathy&#34;
    phenotype_term:
      preferred_term: Diarrhea
      term:
        id: HP:0002014
        label: Diarrhea

  - name: Protein-losing enteropathy
    category: Gastrointestinal
    description: &gt;
      Loss of plasma proteins into the gastrointestinal lumen, resulting in hypoalbuminemia, edema, and immune dysfunction.
      Mucosal inflammation with epithelial damage and villous atrophy leads to significant protein loss and nutritional compromise.
    frequency: FREQUENT
    evidence:
      - reference: PMID:33163187
        supports: SUPPORT
        snippet: &#34;The prognosis of CCS is poor, with a 5-year mortality rate of 55%&#34;
        explanation: &#34;Indicates severe complications from protein-losing enteropathy and malnutrition are major causes of morbidity and mortality&#34;
      - reference: PMID:39470508
        supports: SUPPORT
        snippet: &#34;Other notable symptoms include weight loss, protein-losing enteropathy, diarrhea, abdominal pain, nausea, vomiting, taste abnormalities, and atrophic glossitis, which predominantly occur in middle-aged and older males.&#34;
        explanation: &#34;Confirms protein-losing enteropathy as a notable and frequently occurring symptom in CCS, particularly in middle-aged and older patients&#34;
    phenotype_term:
      preferred_term: Protein-losing enteropathy
      term:
        id: HP:0002243
        label: Protein-losing enteropathy

biochemical:
  - name: Serum albumin
    presence: Decreased
    context: Laboratory marker reflecting protein loss from the gastrointestinal tract; typically &lt;30 g/L in CCS patients
    evidence:
      - reference: PMID:32459145
        supports: SUPPORT
        snippet: &#34;more than 88% of patients exhibit hypoalbuminemia (serum albumin &lt;30 g/L)&#34;
        explanation: &#34;Establishes severely decreased serum albumin as a nearly universal biochemical finding in CCS, occurring in &gt;88% of patients&#34;

  - name: Serum iron
    presence: Decreased
    context: Laboratory marker reflecting chronic GI bleeding or iron malabsorption from damaged intestinal mucosa
    evidence:
      - reference: PMID:32459145
        supports: SUPPORT
        snippet: &#34;Pertinent laboratory findings included hypoalbuminemia (serum albumin, 21.8 g/L) with reduced total protein (46.6 g/L), as well as anemia (serum iron, 74 g/L).&#34;
        explanation: &#34;Case report documents reduced serum iron levels accompanying the severe hypoalbuminemia characteristic of CCS&#34;

  - name: Total serum protein
    presence: Decreased
    context: Laboratory marker reflecting overall protein loss including albumin and globulins
    evidence:
      - reference: PMID:32459145
        supports: SUPPORT
        snippet: &#34;Pertinent laboratory findings included hypoalbuminemia (serum albumin, 21.8 g/L) with reduced total protein (46.6 g/L)&#34;
        explanation: &#34;Case report demonstrates marked reduction in total serum protein reflecting severe protein-losing enteropathy&#34;

treatments:
  - name: Corticosteroids
    description: &gt;
      Systemic corticosteroids (prednisone or methylprednisolone) are the first-line treatment for Cronkhite-Canada syndrome.
      Initial dosages typically range from 30-60 mg/day (1 mg/kg body weight), with gradual dose reduction after symptom improvement. Over 85% of
      patients respond to dosages above 30 mg/day, often resulting in complete remission of polyps and resolution of cutaneous manifestations.
      Glucocorticoids work by reducing gastrointestinal inflammation and suppressing autoimmune responses.
    evidence:
      - reference: PMID:33163187
        supports: SUPPORT
        snippet: &#34;Hormone therapy is the main treatment and prednisone is the major drug. Over 85% of patients responded to a dosage of &gt;30 mg/d&#34;
        explanation: &#34;Establishes corticosteroids as first-line therapy with high response rates in Cronkhite-Canada syndrome&#34;
      - reference: PMID:39470508
        supports: SUPPORT
        snippet: &#34;Hormone therapy has demonstrated significant efficacy in treating this disease. Early treatment and regular follow-up for this disease can reduce the risk of cancerous changes and related complications.&#34;
        explanation: &#34;Recent case report confirms hormone therapy efficacy and emphasizes importance of early treatment in preventing cancer progression&#34;
      - reference: PMID:32459145
        supports: SUPPORT
        snippet: &#34;Glucocorticoid dosage is generally considered to be based on body weight (1 mg/kg); its therapeutic mechanism may involve reduction of gastrointestinal inflammation and inhibition of autoimmune responses.&#34;
        explanation: &#34;Detailed case report establishes dosing rationale and mechanism of action for glucocorticoid therapy in CCS&#34;
      - reference: PMID:36781513
        supports: SUPPORT
        snippet: &#34;All patients received an initial prednisone dose equivalence of 30-80 mg daily, and five patients required steroids at the time of the last follow-up.&#34;
        explanation: &#34;Large cohort study confirms prednisone dosing range and documents sustained steroid requirement in subset of patients for long-term disease control&#34;
      - reference: PMID:34002159
        supports: SUPPORT
        snippet: &#34;It is necessary to extend the duration of prednisone maintenance therapy for CCS. Prednisone is still effective when readministered after relapse.&#34;
        explanation: &#34;Case report demonstrates importance of extended maintenance therapy and confirms effectiveness of steroid retreatment after relapse&#34;
    treatment_term:
      preferred_term: corticosteroid agent therapy
      term:
        id: MAXO:0000640
        label: corticosteroid agent therapy

  - name: Immunosuppressive agents
    description: &gt;
      Azathioprine, cyclosporine, and anti-TNF agents (infliximab) are used in patients with steroid-dependent or steroid-refractory disease.
      Azathioprine shows high response rates and is often used as steroid-sparing therapy. Pharmacogenetic testing for TPMT and NUDT15
      variants is recommended to guide dosing. High TNF-α expression in CCS explains responsiveness to anti-TNF therapy. Combination therapy
      with corticosteroids and azathioprine can lead to marked clinical and endoscopic improvements.
    evidence:
      - reference: PMID:33163187
        supports: SUPPORT
        snippet: &#34;Some patients with hormone-treatment failure or hormone resistance were treated with immunosuppressive agents, such as cyclosporine, azathioprine, and sirolimus, which were also effective&#34;
        explanation: &#34;Documents effectiveness of multiple immunosuppressive agents in corticosteroid-refractory Cronkhite-Canada syndrome&#34;
      - reference: PMID:32459145
        supports: SUPPORT
        snippet: &#34;Other immunosuppressive agents, such as tacrolimus, have been shown to exhibit partial effects.&#34;
        explanation: &#34;Case report confirms tacrolimus and other immunosuppressive agents as effective therapeutic options for CCS management&#34;
      - reference: PMID:40709433
        supports: SUPPORT
        snippet: &#34;The patient was treated with a combination of corticosteroids and azathioprine, which led to marked clinical and endoscopic improvements.&#34;
        explanation: &#34;Recent case demonstrates efficacy of combination corticosteroid and azathioprine therapy with sustained remission on 1-year follow-up&#34;
      - reference: PMID:36781513
        supports: SUPPORT
        snippet: &#34;Twelve patients trialed thiopurine therapy, and ten patients continued with a thiopurine until the last follow-up.&#34;
        explanation: &#34;Large cohort study documents long-term tolerability and sustained use of thiopurine therapy in majority of CCS patients for maintaining remission&#34;
      - reference: PMID:32669505
        supports: SUPPORT
        snippet: &#34;Calcineurin inhibitors such as CyA might have potential therapeutic efficacy for CCS associated with MN.&#34;
        explanation: &#34;Case report demonstrates cyclosporine A as promising therapeutic option for CCS with autoimmune complications&#34;
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy

  - name: Supportive care
    description: &gt;
      Nutritional support including high-protein diet, micronutrient supplementation, fluid replacement, and electrolyte monitoring
      are essential for managing complications of protein-losing enteropathy including hypoalbuminemia, anemia, and malnutrition.
    evidence:
      - reference: PMID:33163187
        supports: SUPPORT
        snippet: &#34;Symptomatic treatment and nutritional-support therapy&#34;
        explanation: &#34;Emphasizes the importance of nutritional support in comprehensive Cronkhite-Canada syndrome management&#34;
      - reference: PMID:39470508
        supports: SUPPORT
        snippet: &#34;Treatment included hormones with antiallergic medication, acid-suppressing drugs, salicylates, and nutritional support with zinc sulfate, adding trace elements and amino acids.&#34;
        explanation: &#34;Recent case demonstrates comprehensive multimodal supportive care approach including trace elements and amino acid supplementation&#34;
    treatment_term:
      preferred_term: supportive care
      term:
        id: MAXO:0000950
        label: supportive care

differential_diagnoses:
  - name: Ulcerative Colitis
    disease_term:
      preferred_term: ulcerative colitis
      term:
        id: MONDO:0005101
        label: ulcerative colitis
    description: &gt;
      Early-stage CCS can present with abdominal pain, diarrhea, bloody stool, and colonoscopy findings of colitis-like appearance,
      making it clinically indistinguishable from ulcerative colitis. Both conditions present with chronic diarrhea, gastrointestinal
      inflammation, and mucosal changes. However, CCS typically involves the entire GI tract including the small intestine and is
      accompanied by distinctive cutaneous manifestations (alopecia, nail dystrophy, hyperpigmentation) that develop later in the disease course.
    distinguishing_features:
      - Distinctive cutaneous triad of alopecia, onychodystrophy, and hyperpigmentation (pathognomonic for CCS, absent in UC)
      - Involvement of small intestine and stomach (seen in ~80-90% of CCS vs. rare in UC)
      - Hamartomatous rather than inflammatory polyps on histology (UC shows crypt distortion and epithelial damage)
      - Taste loss and hypogeusia (characteristic early symptom of CCS, absent in UC)
      - Protein-losing enteropathy is typical of CCS but less prominent in UC
      - CCS spares the esophagus while UC is limited to colon/rectum
    evidence:
      - reference: PMID:33163187
        supports: SUPPORT
        snippet: &#34;Early-stage CCS may manifest as inflammatory bowel disease, e.g. intermittent abdominal pain, diarrhea, mucous, and bloody stool, and colonoscopy showing a colitis-like appearance... Therefore, CCS may be misdiagnosed as ulcerative colitis&#34;
        explanation: &#34;Establishes ulcerative colitis as a primary diagnostic mimicker, particularly in early disease stages&#34;
      - reference: PMID:37674882
        supports: SUPPORT
        snippet: &#34;endoscopic features of diffuse gastric mucosa nodularity with circumferential nodular pancolitis and a solitary colonic polyp initially mimicking inflammatory bowel disease.&#34;
        explanation: &#34;Recent case demonstrates how CCS can mimic IBD with circumferential pancolitis, requiring careful endoscopic and histological assessment for differentiation&#34;

  - name: Peutz-Jeghers Syndrome
    disease_term:
      preferred_term: Peutz-Jeghers syndrome
      term:
        id: MONDO:0008280
        label: Peutz-Jeghers syndrome
    description: &gt;
      Both PJS and CCS present with gastrointestinal polyposis and can have cutaneous manifestations. PJS is characterized by
      hamartomatous polyps throughout the GI tract and characteristic mucocutaneous pigmentation. However, the clinical presentation,
      genetic basis, and associated systemic features differ significantly. PJS polyps are typically larger and less diffuse than
      in CCS, and PJS carries increased cancer risk through a different mechanism (STK11 mutations).
    distinguishing_features:
      - Characteristic mucocutaneous pigmentation (dark macules on lips and oral mucosa) in PJS; hyperpigmentation in CCS is typically truncal and acral
      - PJS is autosomal dominant (STK11 mutations); CCS is nonhereditary and sporadic
      - PJS polyps are typically larger (&gt;1 cm), fewer in number, and predominantly in small intestine; CCS polyps are smaller, more diffuse, and widespread
      - Alopecia and nail dystrophy are characteristic of CCS but absent in PJS
      - PJS presents in childhood; CCS typically presents in middle-aged adults
      - Taste loss is characteristic of CCS, absent in PJS
    evidence:
      - reference: PMID:33163187
        supports: SUPPORT
        snippet: &#34;Typical digestive-tract polyps need to be differentiated from the following: Peutz–Jeghers syndrome, familial adenomatous polyposis, juvenile polyposis, Cowden disease, cap polyposis, and Ménétrier&#39;s disease&#34;
        explanation: &#34;Identifies Peutz-Jeghers syndrome as a key differential diagnosis for CCS based on overlapping GI polyposis presentation&#34;

  - name: Eosinophilic Gastroenteritis
    disease_term:
      preferred_term: eosinophilic gastroenteritis
      term:
        id: MONDO:0016129
        label: eosinophilic gastroenteritis
    description: &gt;
      EGE presents with similar symptoms to CCS including chronic diarrhea, abdominal pain, and GI inflammation with mucosal edema.
      Early in the disease course, before polyp formation is evident, patients with CCS may present with diffuse gastroduodenal mucosal
      edema and eosinophilic infiltration that resembles EGE. Both conditions can present with protein-losing enteropathy and nutritional
      deficiencies. Careful endoscopy and follow-up imaging are required to differentiate the two conditions.
    distinguishing_features:
      - Characteristic peripheral eosinophilia and elevated IgE are common in EGE but not typical of CCS
      - Histology shows predominantly eosinophilic infiltration (&gt;20 eosinophils/hpf) in EGE vs. mixed inflammatory infiltrate in CCS
      - Diffuse polyp formation throughout the GI tract is characteristic of CCS; EGE primarily presents with mucosal thickening and edema
      - Alopecia, nail dystrophy, and hyperpigmentation are specific to CCS
      - Food allergy history is common in EGE; CCS etiology is unknown but may relate to autoimmune mechanisms
      - Follow-up endoscopy typically shows polyp development in CCS but not in EGE
    evidence:
      - reference: PMID:33163187
        supports: SUPPORT
        snippet: &#34;the patient was initially misdiagnosed as having eosinophilic gastroenteritis. However, gastric mucosal atrophy and numerous polyps of the entire digestive tract were found several weeks later.&#34;
        explanation: &#34;Documents diagnostic confusion between CCS and eosinophilic gastroenteritis in early disease stages without evident polyps&#34;

  - name: Familial Adenomatous Polyposis
    disease_term:
      preferred_term: classic familial adenomatous polyposis
      term:
        id: MONDO:0021055
        label: classic familial adenomatous polyposis
    description: &gt;
      FAP presents with hundreds to thousands of adenomatous polyps throughout the colon and rectum, similar to the polyposis seen in CCS.
      Both conditions carry significant cancer risk and require surveillance and intervention. However, FAP is autosomal dominant (APC mutations)
      whereas CCS is sporadic and nonhereditary. The polyp types, anatomical distribution, and systemic manifestations are distinctly different.
    distinguishing_features:
      - FAP is autosomal dominant with positive family history; CCS is sporadic and nonhereditary
      - FAP polyps are adenomatous; CCS polyps are hamartomatous
      - FAP polyps are typically limited to colon/rectum with upper GI involvement in ~25% of cases; CCS involves entire GI tract
      - Extraintestinal manifestations in FAP (congenital hypertrophy of retinal pigment epithelium, desmoid tumors, osteomas) are absent in CCS
      - Distinctive cutaneous triad (alopecia, nail changes, hyperpigmentation) is specific to CCS
      - FAP typically presents in childhood/adolescence; CCS presents in middle-aged adults
    evidence:
      - reference: PMID:33163187
        supports: SUPPORT
        snippet: &#34;Typical digestive-tract polyps need to be differentiated from the following: Peutz–Jeghers syndrome, familial adenomatous polyposis, juvenile polyposis, Cowden disease, cap polyposis, and Ménétrier&#39;s disease&#34;
        explanation: &#34;Identifies FAP as a key differential diagnosis for gastrointestinal polyposis presentation in CCS&#34;

notes: &gt;
  Cronkhite-Canada syndrome is a rare disorder with unknown etiology. Most patients respond to corticosteroid therapy,
  but long-term management and monitoring for malignancy is essential. The condition carries increased risk of gastrointestinal
  malignancies including colorectal cancer, gastric cancer, and esophageal cancer, making regular endoscopic surveillance critical.
  The condition requires multidisciplinary care including gastroenterology, dermatology, and nutritional support. Serious metabolic
  complications including electrolyte abnormalities (particularly hypokalemia from protein-losing enteropathy) can predispose to
  cardiac arrhythmias, requiring careful electrolyte monitoring and cardiac surveillance. Extended duration of maintenance corticosteroid
  therapy is often necessary to prevent relapse. Early recognition and prompt immunosuppressive therapy are critical for preventing
  complications and improving patient outcomes.
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Cronkhite-Canada_syndrome.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>